Skip to main content

Щоб торгувати в США, перейдіть на polymarket.us

icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

5% шанс
Polymarket

$135,595 Обс.

5% шанс
Polymarket

$135,595 Обс.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or widespread availability in 2026, as all candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Official surveillance data confirm no licensed products for U.S. or European strains like Sin Nombre or Andes virus, while existing inactivated vaccines target only select Asian strains and lack broad efficacy. Recent mRNA and DNA platforms from Moderna, UTMB, and others have shown promise in rodent models, yet timelines for human trials, regulatory review, and manufacturing extend well beyond this year. A May 2026 cruise-ship outbreak heightened visibility without accelerating development enough to meet 2026 thresholds.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$135,595
Дата завершення
Jan 1, 2027
Ринок відкрито
May 4, 2026, 10:39 AM ET

Вирішувач

0x65070BE91...
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or widespread availability in 2026, as all candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Official surveillance data confirm no licensed products for U.S. or European strains like Sin Nombre or Andes virus, while existing inactivated vaccines target only select Asian strains and lack broad efficacy. Recent mRNA and DNA platforms from Moderna, UTMB, and others have shown promise in rodent models, yet timelines for human trials, regulatory review, and manufacturing extend well beyond this year. A May 2026 cruise-ship outbreak heightened visibility without accelerating development enough to meet 2026 thresholds.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$135,595
Дата завершення
Jan 1, 2027
Ринок відкрито
May 4, 2026, 10:39 AM ET

Вирішувач

0x65070BE91...

Пов'язане

icon for Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

3%
icon for New pandemic in 2026?

New pandemic in 2026?

5%
icon for Ebola pandemic in 2026?

Ebola pandemic in 2026?

3%

Обережно з зовнішніми посиланнями.

Часті запитання

«Hantavirus vaccine in 2026?» — це ринок прогнозів на Polymarket, де трейдери купують і продають акції «Так» або «Ні» залежно від того, чи вірять вони, що ця подія станеться. Поточна краудсорсингова ймовірність — 5% для «Yes». Наприклад, якщо «Так» коштує 5¢, ринок колективно оцінює шанс цієї події в 5%. Ці шанси безперервно змінюються, коли трейдери реагують на нові події. Акції правильного результату погашаються по $1 кожна при вирішенні ринку.

Станом на сьогодні, «Hantavirus vaccine in 2026?» згенерував $135.6K загального обсягу торгів з моменту запуску ринку May 4, 2026. Цей рівень торгової активності відображає сильну залученість спільноти Polymarket та забезпечує, що поточні шанси базуються на глибокому пулі учасників ринку. Ви можете відстежувати рухи цін наживо та торгувати будь-яким результатом прямо на цій сторінці.

Щоб торгувати на «Hantavirus vaccine in 2026?», просто оберіть, чи вірите ви, що відповідь — «Так» або «Ні». Кожна сторона має поточну ціну, що відображає ймовірність ринку. Введіть суму та натисніть «Торгувати». Якщо ви купили акції «Так» і результат — «Так», кожна акція виплачує $1. Якщо «Ні» — ваші акції «Так» коштують $0. Ви також можете продати акції в будь-який час до вирішення.

Поточна ймовірність для «Hantavirus vaccine in 2026?» — 5% для «Yes». Це означає, що спільнота Polymarket вважає, що є 5% шанс, що ця подія станеться. Ці шанси оновлюються в реальному часі.

Правила вирішення для «Hantavirus vaccine in 2026?» точно визначають, що має статися для оголошення переможця — включаючи офіційні джерела даних. Ви можете переглянути повні критерії вирішення в розділі «Правила» на цій сторінці. Рекомендуємо уважно прочитати правила перед торгівлею.